NYSE:CBM - Cambrex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$43.09 +0.34 (+0.80 %)
(As of 01/16/2019 10:19 AM ET)
Previous Close$42.75
Today's Range$42.72 - $43.69
52-Week Range$35.98 - $69.43
Volume25,574 shs
Average Volume384,630 shs
Market Capitalization$1.48 billion
P/E Ratio13.59
Dividend YieldN/A
Beta2.4
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP13201110
Phone201-804-3000

Debt

Current Ratio4.54
Quick Ratio3.41

Price-To-Earnings

Sales & Book Value

Annual Sales$534.46 million
Price / Sales2.71
Cash Flow$4.1314 per share
Price / Cash Flow10.43
Book Value$16.62 per share
Price / Book2.59

Profitability

Net Income$102.45 million
Net Margins22.67%
Return on Assets14.86%

Miscellaneous

Employees1,228
Market Cap$1.48 billion
OptionableOptionable

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) issued its earnings results on Thursday, November, 8th. The biotechnology company reported $0.49 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.59 by $0.10. The biotechnology company earned $104.62 million during the quarter, compared to analyst estimates of $122.04 million. Cambrex had a net margin of 22.67% and a return on equity of 22.20%. Cambrex's revenue was down 7.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.55 EPS. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Cambrex.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $2.95-3.09 for the period, compared to the Thomson Reuters consensus estimate of $2.79.

What price target have analysts set for CBM?

5 equities research analysts have issued 12 month price objectives for Cambrex's stock. Their forecasts range from $63.00 to $75.50. On average, they anticipate Cambrex's share price to reach $69.25 in the next year. This suggests a possible upside of 60.7% from the stock's current price. View Analyst Price Targets for Cambrex.

What is the consensus analysts' recommendation for Cambrex?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.

Has Cambrex been receiving favorable news coverage?

Media stories about CBM stock have trended positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cambrex earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the company's share price in the near future.

Who are some of Cambrex's key competitors?

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Steven M. Klosk, President, Chief Executive Officer & Director
  • Shawn P. Cavanagh, Chief Operating Officer & Executive Vice President
  • Gregory P. Sargen, Chief Financial Officer
  • James G. Farrell, Vice President & Controller
  • Samantha M. Hanley, Secretary, Vice President & General Counsel

Who are Cambrex's major shareholders?

Cambrex's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Copper Rock Capital Partners LLC (1.17%), Summit Creek Advisors LLC (0.68%), Confluence Investment Management LLC (0.28%), Scout Investments Inc. (0.27%), IMA Wealth Inc. (0.10%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

Which institutional investors are selling Cambrex stock?

CBM stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Louisiana State Employees Retirement System, Confluence Investment Management LLC, Scout Investments Inc., IMA Wealth Inc. and 6 Meridian. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.

Which institutional investors are buying Cambrex stock?

CBM stock was purchased by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Fox Run Management L.L.C. and State of Alaska Department of Revenue. View Insider Buying and Selling for Cambrex.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $43.09.

How big of a company is Cambrex?

Cambrex has a market capitalization of $1.48 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

What is Cambrex's official website?

The official website for Cambrex is http://www.cambrex.com.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (NYSE CBM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel